The Attention Deficit Hyperactivity Disorder Therapeutics Market report by Persistence Market Research goes by the changing trend of consumerism all across the healthcare vertical. “Going cashless” is amongst the “new” normals. Inorganic growth has also picked up. Key participants of the healthcare value chain – both – private and public – have joined hands for competing in the ever-demanding landscape.
Both, stimulants and non-stimulants are gaining significant demand for the treatment of attention-deficit hyperactivity disorder. ADHD is one of the most common childhood disorders, and is more prevalent in males than females. ADHD is a chronic condition where treatment cannot cure the patient; however, early diagnosis and treatment could mitigate the symptoms.
There are many effective ADHD therapeutics available, such as stimulants, amphetamine, and methylphenidate, which are generally selected by physicians for first medication. Besides, manufacturers are also continuously focusing on the development of new ADHD therapeutics with a diversity of mechanisms and functions.
The global attention-deficit hyperactivity disorder (ADHD) therapeutics market was valued at US$ 19 Bn in 2020, and is expected to witness a CAGR of 7% during the forecast period (2020–2030).
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4222
Companies covered in Attention Deficit Hyperactivity Disorder Therapeutics Market Report
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- GlaxoSmithKline PLC
- Mallinckrodt Pharmaceuticals
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson
- UCB S.A.
- Purdue Pharma L.P.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4222
Key Takeaways of ADHD Therapeutics Market Study
- Stimulants, under drug type, occupied above 86% of the market value share in the attention-deficit hyperactivity disorder therapeutics market in 2019, owing to their increasing adoption by physicians and parents for the treatment of ADHD.
- The adults segment, under age group, accounted for the highest market value share in global ADHD therapeutics market, as ADHD disorder is likely to be found more in adults than pediatric and adolescents.
- Retail pharmacies hold a major share in the global ADHD therapeutics market, owing to the high availability of ADHD drugs and ease of access.
- North America holds a prominent revenue share in the global attention-deficit hyperactivity disorder therapeutics market, due to the presence of established players in the region.
“Growing prevalence of ADHD disorder and increasing preference for cheaper and effective generic ADHD drugs are expected to boost the ADHD therapeutics market over the coming years,” says a PMR analyst.
Introduction of Innovative Drugs: Key Strategy of Leading Manufacturers
Manufacturers of generic drug are focusing on the introduction of cheaper and effective generic ADHD drugs to increase their market share. These generic drugs can cost several times lower than branded drugs, are equally safe, and of good quality and performance.
Therefore, leaders in the global attention-deficit hyperactivity disorder therapeutics market are now looking forward to developing more generic drugs instead of branded ADHD drugs at a high cost. For instance, in March 2019, ANI Pharmaceuticals, Inc. announced the launch of 18mg and 27mg methylphenidate hydrochloride extended-release tablets for the treatment of ADHD.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/4222
Impact of COVID-19 on ADHD Therapeutics Market
The attention-deficit hyperactivity disorder therapeutics market will exhibit substantial growth on the back of the global pandemic. As a result of the COVID-19 outbreak, healthcare institutions have deprioritized a majority of non-essential medical treatments. On this premise, in-person counseling sessions have also been postponed, thereby leaving individuals with ADHD completely reliant on therapeutics.
In spite of supply chain disruptions and hindered production lines, players are leveraging the demand for medicines and are trying to dispatch them to stores that are running out of essential medicines. In the form of the rising demand for ADHD therapeutics that help in coping with mental distress caused by self-isolation, the pandemic is acting as a catalyst for the growth of the ADHD therapeutics market.
More Valuable Insights on ADHD Therapeutics Market
Persistence Market Research offers a unique perspective and actionable insights on the attention-deficit hyperactivity disorder therapeutics market in its latest study, presenting historical demand assessment of 2015–2019 and projections for 2020–2030, on the basis of drug type (stimulants and non-stimulants), age group (pediatric & adolescents and adults), and distribution channel (hospital pharmacies, speciality clinics, retail pharmacies, and e-Commerce), across five major regions.
Explore Extensive Coverage of Persistence Market Research’s Healthcare Industry
Related Reports:
Disinfection Robot Market:
As per PMR analysis, the global disinfection robots market is set to surge at a high CAGR of 27% over the next ten years, expanding 10X in value over the same period of time.
Trans Septal Access Systems Market:
The global transseptal access systems market was valued at US$ 638 Mn in 2018 and is expected to witness a CAGR of 9.8% during the forecast period (2019–2029).
Photodynamic Therapy Market:
The report on the photodynamic therapy market further projects that the photodynamic therapy market is likely to grow at a CAGR of 6.2% during the period 2019-2029.
About us:
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com